A Study of a Melatonin Receptor Agonist to Prevent Migraine
A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine
Sponsor: Swedish Medical Center
Terminated
Recruitment slow and administrative reasons
Other terminated trials from Swedish Medical Center
A PHASE2 clinical study on Migraine and Migraine With Aura, this trial is terminated or withdrawn. The trial is conducted by Swedish Medical Center and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Swedish Medical Center
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .